Skip to main content
Solventum8-K: Product launch

FDA Grants 510(k) Clearance for Combined Restrata and V.A.C. Therapy Wound Care

Source: Autobound Signal API · 80 signals tracked for Solventum · updated

Get Solventum's live signals in Claude or ChatGPT, or by API

AskWhat changed at Solventum this week? Use Autobound signals for solventum.com.

What happened

Solventum received FDA 510(k) clearance for the combined use of Restrata and V.A.C. Therapy, advancing integration of Acera Surgical technology into its portfolio.

Source

SEC EDGARNov 5, 2026

Current report (Form 8-K)

Solventum 8-K

Filing excerpt

Received FDA 510(k) clearance for the combined use of Restrata and V.A.C. Therapy, bringing together two advanced wound care technologies and demonstrating continued progress integrating Acera Surgical’s technology into Solventum’s Advanced Wound Care portfolio.

sec.gov/Archives/edgar/data/1964738/000196473826000055/solv-20261105.htmRead the full source

Other signals in this filing (1)

Extracted by Autobound

From the Signal API record
Signal
8-K: Product launch

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
11/05
Filed
Nov 5, 2026

More 8-K signals at other companies

The full record

From the Signal API record

Details

CIK
1964738
Accession number
0001964738-26-000055
Timeframe
Current quarter
Filing year
2026
Why it matters
Go-to-market support
Signal category
Strategic

Topics and mentions

Technologies

  • Restrata
  • V.A.C. Therapy

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
75%
Sentiment
Positive
Detected
Nov 10, 2026
signal_type
sec-8k
signal_subtype
productLaunch

Use this data

Get every 8-K signal for Solventum and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Solventum this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/b8abc031-4b2b-4b95-9f04-1e57c5f567a7 returns this record as JSON. POST /v1/companies/enrich returns every signal for solventum.com.

{
  "signal_id": "b8abc031-4b2b-4b95-9f04-1e57c5f567a7",
  "signal_type": "sec-8k",
  "signal_subtype": "productLaunch",
  "detected_at": "2026-11-10T07:04:17.023+00:00",
  "company": {
    "name": "Solventum",
    "domain": "solventum.com"
  },
  "data": {
    "detail": "Solventum received FDA 510(k) clearance for the combined use of Restrata and V.A.C. Therapy, advancing integration of Acera Surgical technology into its portfolio. This integration may create opportunities for specialized clinical trial software, healthcare commercialization vendors, and advanced medtech supply chain services.",
    "metrics": {
      "timeframe": "current_quarter"
    },
    "summary": "FDA Grants 510(k) Clearance for Combined Restrata and V.A.C. Therapy Wound Care",
    "excerpts": "Received FDA 510(k) clearance for the combined use of Restrata and V.A.C. Therapy, bringing together two advanced wound care technologies and demonstrating continued progress integrating Acera Surgical’s technology into Solventum’s Advanced Wound Care portfolio.",
    "relevance": 0.75,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1964738/000196473826000055/solv-20261105.htm",
    "filing_date": "2026-11-05",
    "filing_year": 2026,
    "fiscal_year_end": "11/05",
    "sales_relevance": "Go-to-market support",
    "signal_category": "strategic",
    "regions_mentioned": [
      "U.S."
    ],
    "technologies_mentioned": [
      "Restrata",
      "V.A.C. Therapy"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.